Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 24:17:24-31.
doi: 10.1016/j.ctro.2019.04.017. eCollection 2019 Jul.

Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer

Natasja R Walterbos  1 , Marta Fiocco  2   3 , Karen J Neelis  1 , Yvette M van der Linden  1   4 , Alexandra M J Langers  5 , Marije Slingerland  6 , Wobbe O de Steur  7 , Femke P Peters  1 , Irene M Lips  1
Affiliations

Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer

Natasja R Walterbos et al. Clin Transl Radiat Oncol. .

Abstract

Background and purpose: Although external beam radiotherapy (EBRT) is frequently used for palliative treatment of patients with incurable esophageal cancer, the optimal schedule for symptom control is unknown. This retrospective study evaluated three EBRT schedules for symptom control and investigated possible prognostic factors associated with second intervention and overall survival (OS).

Material and methods: Patients with esophageal cancer treated with EBRT with palliative intent between January 2009 and December 2015 were evaluated. Univariate and multivariate Cox regression models estimated the effect of treatment schedule (20 Gy in 5 fractions, 30 Gy in 10 fractions or 39 Gy in 13 fractions) on OS. To study the effect of prognostic factors on time to second intervention (repeat EBRT, intraluminal brachytherapy or stent placement) a competing risk model with death as competing event was used.

Results: 205 patients received 20 Gy (31%), 30 Gy (38%) or 39 Gy (32%). Improvement of symptoms was observed in 72% with no differences between schedules. Median OS after 20 Gy, 30 Gy and 39 Gy was 4.6 months (95%CI 2.6-6.6), 5.2 months (95%CI 3.7-6.7) and 9.7 months (95%CI 6.9-12.5), respectively. Poor performance status (HR 2.25 (95%CI 1.53-3.29)), recurrent esophageal cancer (HR 1.69 (95%CI 1.15-2.47)) and distant metastasis (HR 1.73 (95%CI 1.27-2.35)) were significantly related to worse OS. Treatment with 30 Gy and 39 Gy was related to longer time to second intervention compared to 20 Gy (adjusted cause specific HR 0.50 (95%CI 0.25-0.99) and 0.27 (95%CI 0.13-0.56), respectively).

Conclusions: Palliative EBRT provides good symptom control in patients with symptomatic esophageal cancer. A higher dose schedule was related to a longer time to second intervention. Hence, selection based on life expectancy is vital to prevent unnecessary long treatment schedules in patients with expected short survival, and limit the chance of second intervention when life expectancy is longer.

Keywords: Effectiveness; Esophageal cancer; External beam radiotherapy; Palliation; Second intervention; Survival.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival by EBRT treatment schedules.
Fig. 2
Fig. 2
Estimated overall survival by prognostic variables; Karnofsky performance status (KPS), current presentation, tumour length and distant metastasis present at baseline (M stage).
Fig. 3
Fig. 3
Cumulative incidence of second intervention after palliative EBRT in patients with esophageal cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr; 2013 [accessed 23-11-2016]. - PubMed
    1. The Netherlands Cancer Registry. Incidence, Survival and Mortality Cancer Oesophagus. www.dutchcancerfigures.nl; 2017 [accessed 01-03-2017].
    1. Dai Y., Li C., Xie Y., Liu X., Zhang J., Zhou J. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2014;10:Cd005048. - PMC - PubMed
    1. Homs M.Y., Steyerberg E.W., Eijkenboom W.M., Tilanus H.W., Stalpers L.J., Bartelsman J.F. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 2004;364(9444):1497–1504. - PubMed
    1. Fuccio L., Mandolesi D., Farioli A., Hassan C., Frazzoni L., Guido A. Brachytherapy for the palliation of dysphagia owing to esophageal cancer: a systematic review and meta-analysis of prospective studies. Radiother Oncol. 2017;122(3):332–339. - PubMed

LinkOut - more resources